PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles
Nature Communications Open Access 24 July 2023
-
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Molecular Cancer Open Access 20 June 2020
-
Clinical protein science in translational medicine targeting malignant melanoma
Cell Biology and Toxicology Open Access 21 March 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Helleday, T. Mol. Oncol. 5, 387–393 (2011).
Berti, M. et al. Nat. Struct. Mol. Biol. 20, 347–354 (2013).
Schlacher, K. et al. Cell 145, 529–542 (2011).
Schlacher, K., Wu, H. & Jasin, M. Cancer Cell 22, 106–116 (2012).
Wang, A. T. et al. Mol. Cell 59, 478–490 (2015).
Ying, S., Hamdy, F. C. & Helleday, T. Cancer Res. 72, 2814–2821 (2012).
Rondinelli, B. et al. Nat. Cell Biol. 1371–1378 (2017).
Lemaçon, D. et al. Nat. Commun. https://doi.org/10.1038/s41467-017-01180–5 (2017).
Mijic, S. et al. Nat. Commun. https://doi.org/10.1038/s41467-017-01164–5 (2017).
Kolinjivadi, A. M. et al. Mol. Cell 67, 867–881 (2017).
Dungrawala, H. et al. Mol. Cell 67, 374–386 (2017).
Ray Chaudhuri, A. et al. Nature 535, 382–387 (2016).
Sakai, W. et al. Nature 451, 1116–1120 (2008).
Bunting, S. F. et al. Cell 141, 243–254 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Schlacher, K. PARPi focus the spotlight on replication fork protection in cancer. Nat Cell Biol 19, 1309–1310 (2017). https://doi.org/10.1038/ncb3638
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb3638
This article is cited by
-
Targeting ATR in patients with cancer
Nature Reviews Clinical Oncology (2024)
-
RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles
Nature Communications (2023)
-
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Molecular Cancer (2020)
-
Clinical protein science in translational medicine targeting malignant melanoma
Cell Biology and Toxicology (2019)
-
Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia
Blood Cancer Journal (2018)